In the pivotal Phase III trial of pazopanib, PFS was significantly prolonged by pazopanib treatment compared with placebo, regardless of MSKCC risk ... well tolerated in mRCC with poor prognostic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback